Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.
The contract agreement reached Wednesday must still be approved by the union's board and its members, but the leadership said actors will be allowed to return to work starting Thursday.